Evidence map›Paper›PMID 42165829›Full record

ReviewRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer2026

Clinical MR Biomarkers.

Daniel Paech, Sebastian Regnery, Heinz-Peter Schlemmer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniel PaechDivision of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. dpaech@bwh.harvard.edu.
Sebastian RegneryDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Heinz-Peter SchlemmerDivision of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noninvasive magnetic resonance imaging (MRI) techniques are increasingly applied in the clinic with a fast-growing body of evidence regarding their value in diagnostic radiology. In contrast to biochemical or histological markers, the key advantages of imaging biomarkers are the noninvasive nature and the spatial and temporal resolution of these approaches. This chapter focuses on clinical applications of novel MR biomarkers in humans with a strong focus on oncologic diseases. These include both clinically established biomarkers (parts 1-4) and novel MRI techniques that recently demonstrated high potential for clinical utility (parts 5-7).

Indexed as

Biomarkers, TumorMagnetic Resonance ImagingNeoplasmsBiomarkersHumansBiomarkersBiomarkers, TumorChemical Exchange Saturation Transfer (CEST)Diffusion-weighted Imaging (DWI)Metabolic MRI and SpectroscopyMR biomarkersPerfusion-weighted ImagingpHUltra-high field MRI

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.